Direct comparison of the immunogenicity of major histocompatibility complex-I and -II deficient mesenchymal stem cells
CRISPR/Cas9
cell therapy
immune rejection
regenerative medicine
tissue engineering
Journal
Biological chemistry
ISSN: 1437-4315
Titre abrégé: Biol Chem
Pays: Germany
ID NLM: 9700112
Informations de publication
Date de publication:
26 05 2021
26 05 2021
Historique:
received:
10
09
2020
accepted:
19
01
2021
pubmed:
6
2
2021
medline:
16
11
2021
entrez:
5
2
2021
Statut:
epublish
Résumé
Mesenchymal stem cells (MSCs) play an important role in tissue engineering applications aiming at the regeneration or substitution of damaged tissues. In this context, off-the-shelf allogeneic MSCs would represent an attractive universal cell source. However, immune rejection is a major limitation for the clinical use of allogeneic MSCs. Immune rejection is mediated by the expression of major histocompatibility complexes (MHC)-I and -II on the donor cells. In this study, we eliminated MHC-I and/or MHC-II expression in human MSCs by using the CRISPR/Cas9 technology and investigated the effect of the individual or combined knockout of MHC-I and MHC-II on MSC survival after transplantation into immunocompetent mice. Elimination of MHC-I and/or MHC-II expression did not affect mesenchymal marker gene expression, viability, proliferation and the differentiation potential of MSCs
Identifiants
pubmed: 33544464
pii: hsz-2020-0306
doi: 10.1515/hsz-2020-0306
doi:
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
693-702Informations de copyright
© 2021 Walter de Gruyter GmbH, Berlin/Boston.
Références
Abrahimi, P., Chang, W.G., Kluger, M.S., Qyang, Y., Tellides, G., Saltzman, W.M., and Pober, J.S. (2015). Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9. Circ. Res. 117: 121–128, https://doi.org/10.1161/circresaha.117.306290.
Abrahimi, P., Qin, L., Chang, W.G., Bothwell, A.L., Tellides, G., Saltzman, W.M., and Pober, J.S. (2016). Blocking MHC class II on human endothelium mitigates acute rejection. JCI Insight 1, https://doi.org/10.1172/jci.insight.85293.
Balducci, L., Blasi, A., Saldarelli, M., Soleti, A., Pessina, A., Bonomi, A., Cocce, V., Dossena, M., Tosetti, V., Ceserani, V., et al.. (2014). Immortalization of human adipose-derived stromal cells: production of cell lines with high growth rate, mesenchymal marker expression and capability to secrete high levels of angiogenic factors. Stem Cell Res. Ther. 5: 63, https://doi.org/10.1186/scrt452.
Barrachina, L., Remacha, A.R., Romero, A., Vazquez, F.J., Albareda, J., Prades, M., Ranera, B., Zaragoza, P., Martin-Burriel, I., and Rodellar, C. (2016). Effect of inflammatory environment on equine bone marrow derived mesenchymal stem cells immunogenicity and immunomodulatory properties. Vet. Immunol. Immunopathol. 171: 57–65, https://doi.org/10.1016/j.vetimm.2016.02.007.
Barrachina, L., Remacha, A.R., Romero, A., Zaragoza, P., Vazquez, F.J., and Rodellar, C. (2018). Differentiation of equine bone marrow derived mesenchymal stem cells increases the expression of immunogenic genes. Vet. Immunol. Immunopathol. 200: 1–6, https://doi.org/10.1016/j.vetimm.2018.04.004.
Bocker, W., Yin, Z., Drosse, I., Haasters, F., Rossmann, O., Wierer, M., Popov, C., Locher, M., Mutschler, W., Docheva, D., et al.. (2008). Introducing a single-cell-derived human mesenchymal stem cell line expressing hTERT after lentiviral gene transfer. J. Cell Mol. Med. 12: 1347–1359, https://doi.org/10.1111/j.1582-4934.2008.00299.x.
Chan, J.L., Tang, K.C., Patel, A.P., Bonilla, L.M., Pierobon, N., Ponzio, N.M., and Rameshwar, P. (2006). Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 107: 4817–4824, https://doi.org/10.1182/blood-2006-01-0057.
Dale, T.P., de Castro, A., Kuiper, N.J., Parkinson, E.K., and Forsyth, N.R. (2015). Immortalisation with hTERT impacts on sulphated glycosaminoglycan secretion and immunophenotype in a variable and cell specific manner. PLoS One 10: e0133745, https://doi.org/10.1371/journal.pone.0133745.
Das, K., Eisel, D., Lenkl, C., Goyal, A., Diederichs, S., Dickes, E., Osen, W., and Eichmuller, S.B. (2017). Generation of murine tumor cell lines deficient in MHC molecule surface expression using the CRISPR/Cas9 system. PLoS One 12: e0174077, https://doi.org/10.1371/journal.pone.0174077.
Dufrane, D. (2017). Impact of age on human adipose stem cells for bone tissue engineering. Cell Transplant. 26: 1496–1504, https://doi.org/10.1177/0963689717721203.
Fijany, A., Sayadi, L.R., Khoshab, N., Banyard, D.A., Shaterian, A., Alexander, M., Lakey, J.R.T., Paydar, K.Z., Evans, G.R.D., and Widgerow, A.D. (2019). Mesenchymal stem cell dysfunction in diabetes. Mol. Biol. Rep. 46: 1459–1475, https://doi.org/10.1007/s11033-018-4516-x.
Huaman, O., Bahamonde, J., Cahuascanco, B., Jervis, M., Palomino, J., Torres, C.G., and Peralta, O.A. (2019). Immunomodulatory and immunogenic properties of mesenchymal stem cells derived from bovine fetal bone marrow and adipose tissue. Res. Vet. Sci. 124: 212–222, https://doi.org/10.1016/j.rvsc.2019.03.017.
Huang, X.P., Ludke, A., Dhingra, S., Guo, J., Sun, Z., Zhang, L., Weisel, R.D., and Li, R.K. (2016). Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart. Faseb. J. 30: 3069–3082, https://doi.org/10.1096/fj.201600331r.
Huang, X.P., Sun, Z., Miyagi, Y., McDonald Kinkaid, H., Zhang, L., Weisel, R.D., and Li, R.K. (2010). Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 122: 2419–2429, https://doi.org/10.1161/circulationaha.110.955971.
Lechler, R., Batchelor, R., and Lombardi, G. (1991). The relationship between MHC restricted and allospecific T cell recognition. Immunol. Lett. 29: 41–50, https://doi.org/10.1016/0165-2478(91)90197-i.
Lechler, R.I., Lombardi, G., Batchelor, J.R., Reinsmoen, N., and Bach, F.H. (1990). The molecular basis of alloreactivity. Immunol. Today 11: 83–88, https://doi.org/10.1016/0167-5699(90)90033-6.
Lhotakova, K., Grzelak, A., Polakova, I., Vackova, J., and Smahel, M. (2019). Establishment and characterization of a mouse tumor cell line with irreversible downregulation of MHC class I molecules. Oncol. Rep. 42: 2826–2835, https://doi.org/10.3892/or.2019.7356.
Mushahary, D., Spittler, A., Kasper, C., Weber, V., and Charwat, V. (2018). Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytometry A 93: 19–31, https://doi.org/10.1002/cyto.a.23242.
Oh, W., Kim, D.S., Yang, Y.S., and Lee, J.K. (2008). Immunological properties of umbilical cord blood-derived mesenchymal stromal cells. Cell. Immunol. 251: 116–123, https://doi.org/10.1016/j.cellimm.2008.04.003.
Pineiro-Ramil, M., Sanjurjo-Rodriguez, C., Castro-Vinuelas, R., Rodriguez-Fernandez, S., Fuentes-Boquete, I.M., Blanco, F.J., and Diaz-Prado, S.M. (2019). Usefulness of mesenchymal cell lines for bone and cartilage regeneration research. Int. J. Mol. Sci. 20, https://doi.org/10.3390/ijms20246286.
Richardson, S.M., Kalamegam, G., Pushparaj, P.N., Matta, C., Memic, A., Khademhosseini, A., Mobasheri, R., Poletti, F.L., Hoyland, J.A., and Mobasheri, A. (2016). Mesenchymal stem cells in regenerative medicine: focus on articular cartilage and intervertebral disc regeneration. Methods 99: 69–80, https://doi.org/10.1016/j.ymeth.2015.09.015.
Satoh, A., Toyota, M., Ikeda, H., Morimoto, Y., Akino, K., Mita, H., Suzuki, H., Sasaki, Y., Kanaseki, T., Takamura, Y., et al.. (2004). Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-γ-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene 23: 8876–8886, https://doi.org/10.1038/sj.onc.1208144.
Sayegh, M.H., Perico, N., Gallon, L., Imberti, O., Hancock, W.W., Remuzzi, G., and Carpenter, C.B. (1994). Mechanisms of acquired thymic unresponsiveness to renal allografts. Thymic recognition of immunodominant allo-MHC peptides induces peripheral T cell anergy. Transplantation 58: 125–132, https://doi.org/10.1097/00007890-199407270-00001.
Shao, L., Zhang, Y., Pan, X., Liu, B., Liang, C., Zhang, Y., Wang, Y., Yan, B., Xie, W., Sun, Y., et al.. (2020). Knockout of beta-2 microglobulin enhances cardiac repair by modulating exosome imprinting and inhibiting stem cell-induced immune rejection. Cell. Mol. Life Sci. 77: 937–952, https://doi.org/10.1007/s00018-019-03220-3.
Spees, J.L., Lee, R.H., and Gregory, C.A. (2016). Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res. Ther. 7: 125, https://doi.org/10.1186/s13287-016-0363-7.
Steimle, V., Siegrist, C.A., Mottet, A., Lisowska-Grospierre, B., and Mach, B. (1994). Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265: 106–109, https://doi.org/10.1126/science.8016643.
Stenderup, K., Justesen, J., Clausen, C., and Kassem, M. (2003). Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 33: 919–926, https://doi.org/10.1016/j.bone.2003.07.005.
Tu, M.M., Rahim, M.M.A., Sayed, C., Mahmoud, A.B., and Makrigiannis, A.P. (2017). Immunosurveillance and immunoediting of breast cancer via class I MHC receptors. Cancer Immunol. Res. 5: 1016–1028, https://doi.org/10.1158/2326-6066.cir-17-0056.
Ullah, I., Subbarao, R.B., and Rho, G.J. (2015). Human mesenchymal stem cells - current trends and future prospective. Biosci. Rep. 35, https://doi.org/10.1042/BSR20150025.
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., and Ugolini, S. (2008). Functions of natural killer cells. Nat. Immunol. 9: 503–510, https://doi.org/10.1038/ni1582.
Zha, S., Li, Z., Chen, C., Du, Z., Tay, J.C., and Wang, S. (2019). Beta-2 microglobulin knockout K562 cell-based artificial antigen presenting cells for ex vivo expansion of T lymphocytes. Immunotherapy 11: 967–982, https://doi.org/10.2217/imt-2018-0211.
Zhang, Y., Wang, Y., Shao, L., Pan, X., Liang, C., Liu, B., Zhang, Y., Xie, W., Yan, B., Liu, F., et al.. (2020). Knockout of β-2 microglobulin reduces stem cell-induced immune rejection and enhances ischaemic hindlimb repair via exosome/miR-24/Bim pathway. J. Cell Mol. Med. 24: 695–710, https://doi.org/10.1111/jcmm.14778.